En adultos c/HTA resistente y sobrepeso u obesidad, agonistas rec GLP-1 se asocian c/menos riesgos CV y renales que antagonistas rec mineralocorticoides a pesar de reducciones similares de la presión arterial #GLP1RA #MRA #ResistantHypertension www.thelancet.com/journals/ecl...
Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obes...
In our retrospective study, among adults with resistant hypertension and overweight
or obesity, GLP-1RA was associated with lower cardiovascular and kidney risk compared
with MRAs despite smaller bloo...
www.thelancet.com
October 19, 2026 at 2:13 PM
En adultos c/HTA resistente y sobrepeso u obesidad, agonistas rec GLP-1 se asocian c/menos riesgos CV y renales que antagonistas rec mineralocorticoides a pesar de reducciones similares de la presión arterial #GLP1RA #MRA #ResistantHypertension www.thelancet.com/journals/ecl...
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased cardiovascular mortality compared with controlled blood pressure.
Learn more in this Review: ja.ma/4mRKLYU
Learn more in this Review: ja.ma/4mRKLYU
April 28, 2026 at 3:53 PM
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased cardiovascular mortality compared with controlled blood pressure.
Learn more in this Review: ja.ma/4mRKLYU
Learn more in this Review: ja.ma/4mRKLYU
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased #cardiovascular mortality compared with controlled blood pressure.
📄 Learn more in this Review:
ja.ma/4uYSCHI
📄 Learn more in this Review:
ja.ma/4uYSCHI
March 30, 2026 at 1:00 PM
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased #cardiovascular mortality compared with controlled blood pressure.
📄 Learn more in this Review:
ja.ma/4uYSCHI
📄 Learn more in this Review:
ja.ma/4uYSCHI
【東アジア人治療抵抗性高血圧にはアミロライドも選択肢？
RCT/ JAMA】
韓国、「ARB・CCB・サイアザイド」４週併用でも「SBP≧130」だった118例 [平均55歳] ランダム化、12週観察：
・アミロライド5 mg/日で家庭SBPは13.6 mmHg低下。スピロ
ノラクトン 12.5 mg [14.7 mmHg] に非劣性。
・「診察室SBP<130」達成率にも有意差なし。
x.gd/aZMLe
#Amiloride #ResistantHypertension
RCT/ JAMA】
韓国、「ARB・CCB・サイアザイド」４週併用でも「SBP≧130」だった118例 [平均55歳] ランダム化、12週観察：
・アミロライド5 mg/日で家庭SBPは13.6 mmHg低下。スピロ
ノラクトン 12.5 mg [14.7 mmHg] に非劣性。
・「診察室SBP<130」達成率にも有意差なし。
x.gd/aZMLe
#Amiloride #ResistantHypertension
Spironolactone vs Amiloride for Resistant Hypertension
This randomized trial assesses whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure among patients with resistant hypertension.
x.gd
May 14, 2025 at 11:34 PM
【東アジア人治療抵抗性高血圧にはアミロライドも選択肢？
RCT/ JAMA】
韓国、「ARB・CCB・サイアザイド」４週併用でも「SBP≧130」だった118例 [平均55歳] ランダム化、12週観察：
・アミロライド5 mg/日で家庭SBPは13.6 mmHg低下。スピロ
ノラクトン 12.5 mg [14.7 mmHg] に非劣性。
・「診察室SBP<130」達成率にも有意差なし。
x.gd/aZMLe
#Amiloride #ResistantHypertension
RCT/ JAMA】
韓国、「ARB・CCB・サイアザイド」４週併用でも「SBP≧130」だった118例 [平均55歳] ランダム化、12週観察：
・アミロライド5 mg/日で家庭SBPは13.6 mmHg低下。スピロ
ノラクトン 12.5 mg [14.7 mmHg] に非劣性。
・「診察室SBP<130」達成率にも有意差なし。
x.gd/aZMLe
#Amiloride #ResistantHypertension